Explore how high-dimensional flow cytometry can expand immune profiling and support immunotoxicology studies during preclinical research for drug development.
Learn how developmental and reproductive toxicology study selection supports regulatory decision-making and generates meaningful nonclinical safety data.
NAMs are increasingly used to de-risk preclinical development decisions, yet their broader impact on toxicology will depend on whether they are required or simply encouraged by regulators.